Literature DB >> 35543710

Effects of Pulmonary Rehabilitation on Systemic Inflammation and Exercise Capacity in Bronchiectasis: A Randomized Controlled Trial.

Amanda Souza Araújo1,2, Mara Rúbia Figueiredo1,2, Isabella Lomonaco3, Fernando Lundgren4, Rafael Mesquita5, Eanes Delgado Barros Pereira6.   

Abstract

INTRODUCTION: Bronchiectasis is a chronic condition that is becoming a global health concern.
OBJECTIVE: To examine the effects of pulmonary rehabilitation (PR) on systemic inflammation, exercise capacity, and quality of life in participants with bronchiectasis.
METHODS: Participants were randomized to receive PR (outpatient, three weekly sessions for 3 months) or control intervention (usual care + airway clearance therapy + breathing exercises). Data on laboratory (fibrinogen level) and patient-centered outcomes such as physical fitness [6-min walk test (6MWT)] and quality of life were collected.
RESULTS: A total of 41 participants were evaluated (20 in the intervention group and 21 in the control group). The magnitude of change between baseline and the end of study was greater in the PR group than in the control group-the 6MWT distance increased by a mean of 54 m (54 vs 12 m; p < 0.01), fibrinogen showed a significant reduction (fibrinogen - 92.8 versus - 47.1 mg/dl; p < 0.01), and quality of life improved according to Saint George's Respiratory Questionnaire (SGRQ) (- 7.5 vs 3.2; p < 0.01), which exceeded the minimal clinically important difference of 4 points.
CONCLUSION: PR effectively improved physical fitness, quality of life, and the degree of systemic inflammation, as reflected by changes in 6 MWT, fibrinogen levels and SGRQ scores. This study supports the inclusion of people with bronchiectasis in supervised PR programs.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bronchiectasis; Exercise tolerance; Inflammation; Pulmonary rehabilitation

Mesh:

Substances:

Year:  2022        PMID: 35543710     DOI: 10.1007/s00408-022-00540-3

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  31 in total

1.  Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.

Authors:  Amy E Seitz; Kenneth N Olivier; Jennifer Adjemian; Steven M Holland; D Rebecca Prevots
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

2.  Pulmonary rehabilitation in bronchiectasis: a propensity-matched study.

Authors:  Suhani Patel; Aaron D Cole; Claire M Nolan; Ruth E Barker; Sarah E Jones; Samantha Kon; Julius Cairn; Michael Loebinger; Robert Wilson; William D-C Man
Journal:  Eur Respir J       Date:  2019-01-17       Impact factor: 16.671

3.  Physical activity of patients with bronchiectasis compared with healthy counterparts: A cross-sectional study.

Authors:  Aslihan Cakmak; Deniz Inal-Ince; Hazal Sonbahar-Ulu; Cemile Bozdemir-Ozel; Ozge Ozalp; Ebru Calik-Kutukcu; Melda Saglam; Naciye Vardar-Yagli; Hulya Arikan; Ziya Toros Selcuk; Lutfi Coplu
Journal:  Heart Lung       Date:  2019-09-14       Impact factor: 2.210

4.  Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014.

Authors:  Emily Henkle; Benjamin Chan; Jeffrey R Curtis; Timothy R Aksamit; Charles L Daley; Kevin L Winthrop
Journal:  Chest       Date:  2018-07-25       Impact factor: 9.410

5.  Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.

Authors:  Vijay N Joish; Monica Spilsbury-Cantalupo; Elisabeth Operschall; Ba Luong; Susan Boklage
Journal:  Appl Health Econ Health Policy       Date:  2013-06       Impact factor: 2.561

6.  Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis.

Authors:  Meng-Heng Hsieh; Yueh-Fu Fang; Fu-Tsai Chung; Chung-Shu Lee; Yu-Chen Chang; Yuan-Zhang Liu; Cheng-Hsien Wu; Horng-Chyuan Lin
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

7.  Reclaiming the name 'bronchiectasis'.

Authors:  James D Chalmers; J Stuart Elborn
Journal:  Thorax       Date:  2015-03-19       Impact factor: 9.139

8.  An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation.

Authors:  Martijn A Spruit; Sally J Singh; Chris Garvey; Richard ZuWallack; Linda Nici; Carolyn Rochester; Kylie Hill; Anne E Holland; Suzanne C Lareau; William D-C Man; Fabio Pitta; Louise Sewell; Jonathan Raskin; Jean Bourbeau; Rebecca Crouch; Frits M E Franssen; Richard Casaburi; Jan H Vercoulen; Ioannis Vogiatzis; Rik Gosselink; Enrico M Clini; Tanja W Effing; François Maltais; Job van der Palen; Thierry Troosters; Daisy J A Janssen; Eileen Collins; Judith Garcia-Aymerich; Dina Brooks; Bonnie F Fahy; Milo A Puhan; Martine Hoogendoorn; Rachel Garrod; Annemie M W J Schols; Brian Carlin; Roberto Benzo; Paula Meek; Mike Morgan; Maureen P M H Rutten-van Mölken; Andrew L Ries; Barry Make; Roger S Goldstein; Claire A Dowson; Jan L Brozek; Claudio F Donner; Emiel F M Wouters
Journal:  Am J Respir Crit Care Med       Date:  2013-10-15       Impact factor: 21.405

9.  Respiratory and Peripheral Muscle Weakness and Body Composition Abnormalities in Non-Cystic Fibrosis Bronchiectasis Patients: Gender Differences.

Authors:  Xuejie Wang; Ana Balaña-Corberó; Juana Martínez-Llorens; Liyun Qin; Yingchen Xia; Jianhua Zha; José María Maiques; Esther Barreiro
Journal:  Biomedicines       Date:  2022-01-31

10.  Oxidative and inflammatory effects of pulmonary rehabilitation in patients with bronchiectasis. A prospective, randomized study.

Authors:  Casilda Olveira; Eva García-Escobar; Esperanza Doña; Francisco J Palenque; Nuria Porras; Antonio Dorado; Ana María Godoy; Elezahara Rubio-Martín; Francisco-Javier Bermúdez-Silva; Silvana Y Romero-Zerbo; Gemma Rojo Martínez; Rocío Martín-Valero; José Abuín Fernández; Gabriel Olveira
Journal:  Nutr Hosp       Date:  2020-02-17       Impact factor: 1.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.